DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma
Open Access
- 10 October 2013
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 24 (12), 3045-3050
- https://doi.org/10.1093/annonc/mdt396
Abstract
Squamous cell carcinoma of the anal canal (SCCA) is a rare disease, mostly diagnosed at early stage. After concurrent chemoradiation (CRT) with mitomycin C and 5-fluorouracil (5FU), local or metastatic recurrences occur in >20% of the patients. After treatment failure, cisplatin (CDDP)-based chemotherapy is the standard option, but complete response (CR) is a rare event and the prognosis remains poor. Eight consecutive patients with advanced recurrent SCCA after CRT were treated with DCF regimen (docetaxel 75 mg/m2 day 1, CDDP 75 mg/m2 day 1 and 5FU at 750 mg/m2/day for 5 days every 3 weeks). Tumour samples were analysed for human papillomavirus (HPV) genotyping, as well as p16 and p53 expression. After a median follow-up of 41 months, the overall survival rate at 12 months was 62.5% (95% CI 22.9–86.1 months). Four patients achieved a complete remission and remain relapse-free at the time of analysis with a progression-free survival of 19, 33, 43 and 88 months. Three of these patients underwent surgery for all involved metastatic sites. For all of them, pathological CR was confirmed. DCF regimen appeared feasible in these patients previously exposed to pelvic CRT, and no grade IV toxicity occurred. All patients in complete remission had HPV-16-positive SCCA, while HPV could only be detected among 50% of the non-responding patients. Of interest, immunohistochemical study revealed a p16+/p53− phenotype in these patients, while none of non-responders expressed p16. The high level of complete and long-lasting remission among SCCA patients treated with DCF regimen supports the assessment of this strategy in prospective cohorts.This publication has 16 references indexed in Scilit:
- Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/CisplatinJournal of Clinical Oncology, 2012
- Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 TrialJournal of Clinical Oncology, 2012
- Anal Carcinoma, Version 2.2012Journal of the National Comprehensive Cancer Network, 2012
- Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trialThe Lancet Oncology, 2011
- Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282Investigational New Drugs, 2006
- Anal cancer incidence and survival: The Surveillance, Epidemiology, and End Results experience, 1973–2000Cancer, 2004
- Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomasCancer, 2001
- Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosisNature Medicine, 1996
- The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53Cell, 1990